William Ackman, Pershing Square (Bloomberg) When you think of William Ackman’s large losses in 2015 and so far this year, you immediately think of his badly timed bet on Valeant Pharmaceuticals International and his
To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.